RENAL-FUNCTION IN THE ELIMINATION OF ORAL MELPHALAN IN PATIENTS WITH MULTIPLE-MYELOMA

被引：21

作者：

ADAIR, CG

BRIDGES, JM

DESAI, ZR

机构：

来源：

关键词：

D O I：

10.1007/BF00306752

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：185 / 188

页数：4

共 13 条

[1] MODIFIED EXTRACTION AND CHROMATOGRAPHY FOR THE MEASUREMENT OF PLASMA MELPHALAN BY ION-PAIR HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
ADAIR, CG
BURNS, DT
CROCKARD, AD
DESAI, ZR
HARRIOTT, M
[J]. JOURNAL OF CHROMATOGRAPHY, 1984, 336 (02): : 429 - 433
[2] ALBERTS DS, 1980, RECENT RES CANCER, V74, P124
[3] EFFECT OF RENAL DYSFUNCTION IN DOGS ON THE DISPOSITION AND MARROW TOXICITY OF MELPHALAN
ALBERTS, DS
CHEN, HSG
BENZ, D
MASON, NL
[J]. BRITISH JOURNAL OF CANCER, 1981, 43 (03) : 330 - 334
[4] ALBERTS DS, 1979, CLIN PHARMACOL THER, V26, P737
[5] BOSANQUET AG, 1984, CANCER CHEMOTH PHARM, V12, P183
[6] PHARMACOKINETICS OF ORAL AND INTRAVENOUS MELPHALAN DURING ROUTINE TREATMENT OF MULTIPLE-MYELOMA
BOSANQUET, AG
GILBY, ED
[J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1982, 18 (04): : 355 - 362
[7] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
COCKCROFT, DW
GAULT, MH
[J]. NEPHRON, 1976, 16 (01) : 31 - 41
[8] CORNWELL GG, 1982, CANCER TREAT REP, V66, P475
[9] EVANS TL, 1982, CANCER CHEMOTH PHARM, V8, P175
[10] FURNER RL, 1980, CANCER TREAT REP, V64, P559